Skip to main content

Table 1 Demographic and clinical characteristics of each sample across stages

From: The endometriosis daily diary: qualitative research to explore the patient experience of endometriosis and inform the development of a patient-reported outcome (PRO) for endometriosis-related pain

Description   Stage 1 (N = 30) Stage 2 (N = 30) Stage 3 (N = 15)
Demographic characteristics
Age (years) Mean (Min, max) 29.4 (12, 49) 29.2 (12,49) 32.5 (19, 45)
Length of time experiencing pelvic pain, years Mean (Min–Max) 8.7 (0.5–27) 5.8 (1–16) 7.13 (1- 27)
Race, n (%) White 14 (46.7%) 14 (46.7%) 9 (60.0%)
  Black/African American 12 (40.0%) 9 (30.0%) 3 (20.0%)
  Other 4 (13.3%) 7 (23.3%) 1 (6.7%)
  North African or Alaska Native 0 (0.0%) 0 (0.0%) 1 (6.7%)
  Multi-Racial 0 (0.0%) 0 (0.0%) 1 (6.7%)
Ethnicity, n (%) Non-Hispanic or Latino 18 (60.0%) 21 (70.0%) 9 (60.0%)
  Hispanic or Latino 12 (40.0) 9 (30.0%) 6 (40.0%)
Highest level of education (adults only), n (%) College or university degree 7 (23.3%) 6 (20.0%) 2 (13.3%)
  High school diploma or General Education Diploma 7 (23.3%) 4 (13.3%) 4 (26.7%)
  Some years of college 4 (13.3%) 6 (20.0%) 5 (33.3%)
  Certificate Program 2 (6.7%) 3 (10.0%) 3 (20.0%)
  Graduate or professional degree 0 (0.0%) 1 (6.7%) 1 (6.7%)
Work status, n (%) Working full or part time 17 (56.7%) 19 (63.3%) 13 (86.7%)
  At school or student 10 (33.3%) 9 (30.0%) 1 (6.7%)
  Full time homemaker 3 (10.0%) 2 (6.7%) 1 (6.7%)
Clinical characteristics
Time since diagnosis*, years Less than 5 years 15 (50%) 21 (70.0%) 8 (53.3%)
  6–10 years 6 (20%) 3 (10.0%) 6 (40.0%)
  Over 10 years 9 (30.0%) 6 (20.0%) 1 (6.7%)
Type of chronic pelvic pain, n (%) Cyclic pain only 16 (53.3%) 19 (63.3%) 9 (60.0%)
  Cyclic and non-cyclic pain 14 (46.7%) 11 (36.7%) 6 (40.0%)
Severity of cyclic (menstrual) pelvic pain at screening using 0–10 Numerical Rating Scale (NRS)***, n (%) Mild (1–4) 7 (23.3%) 6 (20.0%) 5 (33.3%)
  Moderate (5–7) 12 (40.0%) 9 (30.0%) 5 (33.3%)
  Severe (8–10) 11 (36.7%) 15 (50.0%) 5 (33.3%)
  Mean (range) 6.53 (3–10) 7.27 (3–10) 6.07 (2–10)
Severity of non-cyclic (non-menstrual) pelvic pain at screening using 0–10 NRS***, n (%) Mild (1–4) 10 (33.3%) 12 (40.0%) 4 (26.7%)
  Moderate (5–7) 13 (43.3%) 9 (30.0%) 7 (46.7%)
  Severe (8–10) 7 (23.3%) 9 (30.0%) 4 (26.7%)
  Mean (range) 5.6 (3–10) 6.13 (3–10) 5.87 (2–10)
Diagnostic procedure, n (%) Surgical diagnosis 30 (100%) 20 (66.7%) 15 (100%)
  Clinically suspected endometriosis 0 (0.0%) 10 (33.3%) 0 (0.0%)
Hormonal therapy, n (%) On hormonal therapy 15 (50.0%) 15 (50.0%) 9 (60.0%)
  Not on hormonal therapy 15 (50.0%) 15 (50.0%) 6 (40.0%)
Current treatment**, pharmacological (non-hormonal), n (%) Nonsteroidal Anti-Inflammatory Drugs 25 (83.3%) 24 (80.0%) 12 (80.0%)
  Other pain medications (incl. Acetaminophen) 2 (6.7%) 15 (50.0%) 4 (26.7%)
  Opiate (incl. codeine, oxycodone) 3 (10%) 3 (10.0%) 1 (6.7%)
  1. *This has been calculated from date of interview
  2. **More than one current/previous treatment was reported for some participants
  3. ***The following interpretative pain severity cut-offs were employed for the 0–10 NRS: 1–4 was considered Mild, 5–7 was considered Moderate, and 8–10 was considered Severe